About the Study

Germ Cell Tumors (GCT): Monitoring patients with low risk GCT and using the drug carboplatin instead of cisplatin for patients with standard risk GCT.

Eligible patients must be diagnosed with having a germ cell tumor (GCT). Patients who are diagnosed with Stage I GCT may be eligible no matter the age. Those ages 0-25 who are diagnosed with Stage II-IV may be eligible depending on the location of the GCT. Researchers want to see if monitoring patients with low risk germ cell tumors after their tumor is removed is as effective as following surgery with chemotherapy and/or more surgery. Researchers also want to compare the effects of carboplatin with cisplatin on patients with standard risk germ cell tumors to find out which is better.

Interested in learning more?

Full Study Name: AGCT1531 - A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors